STOK / Stoke Therapeutics, Inc. (STOK) Surges 6.3%: Is This an Indication of Further Gains?

Stoke Therapeutics (STOK) stock is down 40% after failing to meet expectations in a phase 1/2 epilepsy trial. STOK develops therapies for rare disease more_horizontal

Stoke Therapeutics, Inc. (STOK) came out with a quarterly loss of $0.69 per share versus the Zacks Consensus Estimate of a loss of $0.65. This compare more_horizontal

Stoke Therapeutics' shares hit a 52-week low on Tuesday. The company is testing STK-001 to treat Dravet syndrome, a progressive genetic epilepsy disor more_horizontal

Stoke Therapeutics, Inc. (STOK) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate re more_horizontal

The consensus price target hints at a 102.9% upside potential for Stoke Therapeutics, Inc. (STOK). While empirical research shows that this sought-aft more_horizontal

Stoke Therapeutics, Inc. (STOK) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.70. This compare more_horizontal

Stoke Therapeutics, Inc. (STOK) delivered earnings and revenue surprises of 9.72% and 11.42%, respectively, for the quarter ended December 2022. Do th more_horizontal

STOK went down steadily over the past two years. Its derisking Dravet data did not help either. more_horizontal